Загрузка...
Bevacizumab in the therapy for refractory metastatic colorectal cancer
Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in t...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2727788/ https://ncbi.nlm.nih.gov/pubmed/19707427 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|